The FDA is expediting reviews for Merck’s cholesterol pill enlicitide decanoate and cancer therapy sacituzumab tirumotecan under the Commissioner’s National Priority Voucher program. These drugs, with significant sales potential, are expected to be submitted for approval in 2026. The program, launched in June, aims to accelerate drug approvals with critical public health impacts, reducing review times from 10-12 months to 1-2 months. This move aligns with the Trump administration’s efforts to negotiate drug pricing agreements and enhance the FDA’s capacity to address urgent health needs.
